Bright Minds Biosciences Inc. (DRUG) Cash Flow Statement

The significant divergence between net income and operating cash flow, particularly in quarters like 2025Q1 where a small net profit coincided with a $1.5M operating cash outflow, suggests that accruals and non-cash adjustments are distorting the underlying cash burn. This volatility implies that investors should focus on the operating cash flow trend rather than net income, as the latter is not a reliable indicator of the company's cash consumption during this high-R&D phase.

The FCF trajectory reveals a worsening cash consumption profile that is not fully captured by the net income line, as operating cash outflows have grown more rapidly than accounting losses. This acceleration, particularly the jump from -$1.3M in 2025Q4 to -$8.4M in 2026Q3, suggests the company is entering a more capital-intensive phase of clinical development, which will test the adequacy of its $82.9M cash position.

The inconsistent working capital dynamics, with large swings in accounts payable and receivable, indicate that the company's cash flow is being influenced by the timing of payments to vendors and CROs rather than purely by operational progress. This volatility makes it difficult to assess the underlying cash burn rate on a quarter-to-quarter basis and warrants monitoring for any sustained build-up in receivables that could signal future collection issues.

The complete absence of capital returns or strategic investments confirms that the company is in a pure cash-burn mode, with every dollar of financing being funneled into the clinical pipeline. This singular focus is appropriate for a pre-revenue biotech, but it means the company's survival is entirely dependent on its ability to reach value-inflecting clinical milestones before its cash runway is exhausted.